poisar

Stocks · News reference

Incyte To Present New Phase 1 Solid Tumor Data, Including KRAS G12D and TGFβR2×PD‑1 Programs, At ESMO 2026

Jul 17, 2026, 5:12 PMBenzinga Newsdesk

Rapid oral presentations will highlight new Phase 1 data across Incyte’s solid tumor portfolioBoth INCB161734, an investigational, potent, selective and orally bioavailable KRAS G12D inhibitor, and INCA338901, a

Read original sourceMore stocks news

Reference details

Connected markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

INCY
Source
benzinga
Observed
Jul 17, 2026, 5:12 PM
Checked
Jul 17, 2026, 5:12 PM
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading